# US 2024/0197786 A1 · Mesenchymal Stem Cell Derived Exosomes And Methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197786 A1
- Document ID: US20240197786A1
- Status: Published application
- Kind: A1
- Application number: 18/415,101
- Filed: 2024-01-17
- Published: 2024-06-20
- Earliest claimed: 2018-10-18
- Assignees: NantBio, Inc.
- Applicants: NantBio, Inc.
- Inventors: Patrick Soon-Shiong; Francesco Curcio; Kayvan Niazi
- Web page: https://patentgrep.com/patent/US20240197786A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- A61K 35/13: Tumour cells, irrespective of tissue of origin (tumour vaccines A61K39/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C12N 5/0693: {Tumour cells; Cancer cells}
- C12N 2500/32: Amino acids
- C12N 2500/38: Vitamins
- C12N 2501/105: Insulin-like growth factors [IGF]
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/24: Interferons [IFN]
- C12N 2501/25: Tumour necrosing factors [TNF]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions and methods are presented that include exosomes from stem cells and/or tumor cells that were previously exposed to an inflammatory stimulus. Advantageously, such exosomes exhibit anti-inflammatory and analgesic effect when administered to an individual. Therefore, a preferred use of such exosomes will reduce the need for opioid analgesics, and reduce pain and inflammation.

## Claims

### Claim 1

A method of manufacturing a pharmaceutical composition, comprising:
exposing stem cells and/or tumor cells of an individual ex vivo in a culture medium to an inflammatory stimulus;
harvesting exosomes from the culture medium; and
formulating the harvested exosomes into a pharmaceutical composition suitable for injection or infusion.

### Claim 2 (depends on 1)

The method of claim 1 wherein the stem cells are mesenchymal stem cells, and optionally adipose mesenchymal stem cells.

### Claim 3 (depends on 1)

The method of claim 1 wherein the inflammatory stimulus is selected from the group consisting of IFNγ (interferon gamma), TNFα (tumor necrosis factor alpha), a TLR ligand, a NOD ligand, and a STING (Stimulator of Interferon Genes) activator.

### Claim 4 (depends on 1)

The method of claim 1 wherein the stem cells or the tumor cells are exposed to the inflammatory stimulus in an amount that increases expression of IDO (indoleamine-2,3-dioxygenase) or PGE2 (prostaglandin E2) in the stem cells or the tumor cells, and/or increases IL-6, IL-8, IL10, or CCL-2 in the stem cells or the tumor cells.

### Claim 5 (depends on 1)

The method of claim 1 wherein the stem cells or the tumor cells are exposed to the inflammatory stimulus for at least 24 hours.

### Claim 6 (depends on 1)

The method of claim 1 wherein the exosomes are harvested using a step of ultracentrifugation, a step of polymer precipitation, or a step of affinity separation using an antibody or fragment thereof.

### Claim 7 (depends on 1)

The method of claim 1 wherein the pharmaceutical composition comprises at least 109 harvested exosomes per dosage unit and/or the method further comprises a step of including into the pharmaceutical composition an anti-inflammatory agent and/or an analgesic drug.
